An observational study in Acute Heart Failure and Acute Coronary Syndrome, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by University Hospital, Basel, Switzerland · Observational
Among 42 studies in Acute Coronary Syndrome with a site in Switzerland — 11 open to participants now, 12 under way, 2 of them phase 3. Acute Coronary Syndrome · Switzerland.
Among the 42 studies in Acute Coronary Syndrome with a site in Switzerland, this one is the 3rd largest by planned enrollment of the 13 observational ones, is one of 3 that started in 2019, is one of 13 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 25th registered.
1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
This study's planned enrollment of 6,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →11 of the 42 studies in Acute Coronary Syndrome with a site in Switzerland are open now, in 12 countries. Each count lists the studies.
Of the 196 Acute Coronary Syndrome studies recruiting now, 144 (73%) set no upper age limit and 19 (10%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →42 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2019.
Median enrollment 1,200 across the 29 interventional studies, 2,498 across the 13 observational. Of the 26 that completed or were terminated, 8 (31%) have results posted.
17 of 42 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 2 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Coronary Syndrome with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT07597031Matthias Wilhelm, MDFeasibility Study of a Digital Interactive Life-style Platform for Individuals After Rehabilitation | 2027-02-01 |
| NCT04000061University Hospital, Basel, SwitzerlandHeart Failure-USB: Prediction and Progression | 2027-04-04 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Among the 42 studies in Acute Coronary Syndrome with a site in Switzerland, from their registry updates:
This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.
Patients that were hospitalized at the Universitätsspital Basel/ Switzerland with the diagnosis of ACS or AHF during the years 2010 - 2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary diagnosis of ACS is analyzed.
Other: medical chart review · Other: data generated by direct IT export
Outcome information (all-cause death, heart failure (HF) hospitalizations) of patients hospitalized with a primary or secondary diagnosis of AHF is analyzed.
Other: medical chart review · Other: data generated by direct IT export
data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
number of all-cause death
number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.
Time frame: 1 to 8 years after hospitalization
number of HF hospitalizations
number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023
Time frame: 1 to 8 years after hospitalization
number of cardiovascular death
number of cardiovascular death in patients hospitalized with ACS and AHF
Time frame: 1 to 8 years after hospitalization
number of cardiovascular hospitalizations
number of cardiovascular hospitalizations
Time frame: 1 to 8 years after hospitalization
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2019 (actual). Primary completion is estimated for Apr 2027, 93 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →